Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Research
Trial to study oral spray to reduce chemotherapy-induced nausea
March 10th, 2005
Hana Biosciences, Inc., (BULLETIN BOARD: HNAB) announced an initial clinical study that will compare the pharmacokinetic profile of the lingual spray formulation of ondansetron to the approved oral dosage of Zofran, an antiemetic agent, currently marketed in the U.S. by GlaxoSmithKline. Annual U.S. sales for Zofran were approximately $1.0 billion in 2003, and the product patent expires in June 2006. Based on successful results of this pilot pharmacokinetic trial in healthy volunteers, Hana intends to file an investigational new drug (IND) application to commence an abbreviated clinical development program designed to support a 505(b)(2) submission, a...
Source: Women's Health Weekly (2005-03-10)
|
